Table 1 Characteristics of study participants

Total (N, %)

437

100.0

Age, years

0.26

>65

138

31.6

1

55-65

201

46.0

0.58 (0.30-1.13)

<55

98

22.4

0.81 (0.39-1.68)

Race

0.51

White

360

82.4

1

Non-white

77

17.6

0.77 (0.34-1.72)

Education

0.071

College or above

343

78.7

1

High school or less

93

21.3

0.42 (0.17-1.08)

Years since LMP

0.59

>10

242

56.1

1

5-10

108

25.1

1.42 (0.72-2.77)

<5

81

18.8

1.05 (0.48-2.29)

Reasons for menopause

Natural

226

52.4

1

Induced

205

47.6

1.44 (0.81-2.56)

Comorbid conditions

0.35

None

68

15.6

1

One

133

30.4

0.84 (0.38-1.89)

Two or more

236

54.0

0.59 (0.27-1.30)

Stage

0.46

I

169

38.6

1

II

214

49.0

0.77 (0.42-1.41)

III

54

12.4

0.56 (0.19-1.63)

Chemotherapy

0.92

None

169

38.7

1

Chemotherapy but no taxane

104

23.8

0.92 (0.41-2.05)

Chemotherapy included taxane

164

37.5

1.08 (0.57-2.04)

Years since start of AI

0.66

<1

139

31.8

1

1-3

145

33.2

0.74 (0.39-1.43)

>3

153

35.0

0.81 (0.38-1.76)

Prior tamoxifen use

0.088

No

290

66.4

1

Yes

147

33.6

1.70 (0.94-3.08)

Aromatase inhibitor

0.22

Anastrozole

299

70.1

1

Letrozole

80

18.7

0.57 (0.25-1.30)

Exemestane

47

11.0

0.98 (0.37-2.56)

Patient-reported worst joint pain

0.037

0-3

277

64.0

1

4-10

156

36.0

1.86 (1.04-3.31)

Patient-reported joint pain related to AIs

0.14

No

231

52.9

1

Yes

206

47.1

1.55 (0.87-2.76)